US equities
|
SPCX
$167.66
▲+5.48%
NVDA
$237.25
▲+1.41%
MU
$1,068.78
▼-0.57%
TSLA
$376.73
▲+1.66%
MSFT
$526.54
▲+1.74%
INTC
$116.92
▼-2.02%
SNDK
$1,726.00
▲+0.35%
META
$745.32
▲+2.37%
SPCX
$167.66
▲+5.48%
NVDA
$237.25
▲+1.41%
MU
$1,068.78
▼-0.57%
TSLA
$376.73
▲+1.66%
MSFT
$526.54
▲+1.74%
INTC
$116.92
▼-2.02%
SNDK
$1,726.00
▲+0.35%
META
$745.32
▲+2.37%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Eledon Pharmaceuticals, Inc. - Common Stock
(NQ:
ELDN
)
2.480
-0.010 (-0.40%)
Delayed Quote
Updated: 10:55 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eledon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
September 22, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
September 09, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
September 03, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart
↗
March 19, 2026
Via
Chartmill
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
June 25, 2026
From
Natera, Inc.
Via
Business Wire
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
June 22, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 08, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
June 04, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
May 20, 2026
Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
March 19, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
March 16, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
March 10, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
March 04, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
January 23, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 08, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
December 01, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tuesday's after hours session: top gainers and losers
↗
November 18, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
November 18, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 14, 2025
Via
Benzinga
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
November 12, 2025
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the...
Via
MarketMinute
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
Top movers in Wednesday's pre-market session
↗
November 12, 2025
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
November 12, 2025
Via
Benzinga
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 11, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
November 10, 2025
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results...
Via
MarketMinute
What's going on in today's after hours session
↗
November 07, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
< Previous
1
2
3
4
5
6
Next >
